CD274 and autoimmune disease: The authors analyzed the available literature and identified 56 patients with advanced NSCLC receiving PD-1 or PD-L1 inhibitors who had a history of autoimmune diseases associated with inflammatory changes in the joints, skin and subcutaneous tissue as well as endocrine glands or autoimmune colitis.